Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
|
N Engl J Med
|
2004
|
41.02
|
2
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
33.60
|
3
|
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
|
N Engl J Med
|
2002
|
18.61
|
4
|
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2006
|
16.25
|
5
|
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
11.22
|
6
|
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
|
N Engl J Med
|
2016
|
8.53
|
7
|
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
|
J Clin Oncol
|
2007
|
7.73
|
8
|
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
|
J Natl Cancer Inst
|
2005
|
7.70
|
9
|
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.
|
N Engl J Med
|
2002
|
7.66
|
10
|
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2003
|
6.57
|
11
|
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
|
J Clin Oncol
|
2008
|
6.31
|
12
|
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
|
J Clin Oncol
|
2005
|
6.20
|
13
|
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
|
Cancer Prev Res (Phila)
|
2010
|
5.81
|
14
|
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
|
J Clin Oncol
|
2009
|
5.69
|
15
|
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.
|
Lancet Oncol
|
2007
|
5.39
|
16
|
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
|
N Engl J Med
|
2010
|
5.17
|
17
|
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2006
|
4.99
|
18
|
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
|
J Clin Oncol
|
2011
|
4.81
|
19
|
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
|
J Clin Oncol
|
2010
|
4.81
|
20
|
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
|
Lancet Oncol
|
2010
|
4.81
|
21
|
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
|
J Clin Oncol
|
2005
|
4.77
|
22
|
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
|
J Clin Oncol
|
2005
|
4.66
|
23
|
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
4.57
|
24
|
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
|
J Clin Oncol
|
2012
|
4.33
|
25
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
|
N Engl J Med
|
2012
|
4.10
|
26
|
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
|
J Natl Cancer Inst
|
2002
|
3.99
|
27
|
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
|
J Clin Oncol
|
2009
|
3.99
|
28
|
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
|
Lancet
|
2004
|
3.98
|
29
|
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
|
J Clin Oncol
|
2002
|
3.82
|
30
|
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
|
J Clin Oncol
|
2004
|
3.82
|
31
|
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
J Clin Oncol
|
2010
|
3.79
|
32
|
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
|
J Natl Cancer Inst
|
2011
|
3.54
|
33
|
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
|
J Clin Oncol
|
2007
|
3.51
|
34
|
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
|
J Clin Oncol
|
2010
|
3.19
|
35
|
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
|
Clin Cancer Res
|
2012
|
3.07
|
36
|
HER2 status and benefit from adjuvant trastuzumab in breast cancer.
|
N Engl J Med
|
2008
|
3.05
|
37
|
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
|
J Clin Oncol
|
2011
|
2.88
|
38
|
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
|
J Clin Oncol
|
2006
|
2.83
|
39
|
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
|
J Clin Oncol
|
2006
|
2.81
|
40
|
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
|
J Natl Cancer Inst
|
2006
|
2.77
|
41
|
Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
|
J Natl Cancer Inst
|
2004
|
2.65
|
42
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
|
Lancet Oncol
|
2012
|
2.65
|
43
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.59
|
44
|
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
|
J Clin Oncol
|
2008
|
2.55
|
45
|
Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.
|
J Surg Oncol
|
2010
|
2.52
|
46
|
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
2.38
|
47
|
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
|
J Clin Oncol
|
2009
|
2.34
|
48
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
|
J Clin Oncol
|
2012
|
2.34
|
49
|
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
|
J Clin Oncol
|
2004
|
2.30
|
50
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
|
J Natl Cancer Inst
|
2013
|
2.28
|
51
|
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
|
J Clin Oncol
|
2011
|
2.26
|
52
|
Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
|
J Natl Cancer Inst
|
2004
|
2.21
|
53
|
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
|
J Clin Oncol
|
2012
|
2.19
|
54
|
Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
|
Cancer
|
2002
|
2.18
|
55
|
Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2005
|
2.17
|
56
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
|
J Clin Oncol
|
2013
|
2.12
|
57
|
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
Breast Cancer Res Treat
|
2011
|
2.08
|
58
|
Effect of occult metastases on survival in node-negative breast cancer.
|
N Engl J Med
|
2011
|
1.95
|
59
|
Letrozole after tamoxifen for breast cancer--what is the price of success?
|
N Engl J Med
|
2003
|
1.90
|
60
|
Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
|
J Natl Cancer Inst
|
2004
|
1.88
|
61
|
Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
|
J Clin Oncol
|
2003
|
1.87
|
62
|
Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
|
Am J Obstet Gynecol
|
2005
|
1.83
|
63
|
Association of tamoxifen and uterine sarcoma.
|
J Clin Oncol
|
2002
|
1.80
|
64
|
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
|
J Clin Oncol
|
2007
|
1.77
|
65
|
The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06.
|
Cancer
|
2003
|
1.77
|
66
|
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.
|
Cancer Prev Res (Phila)
|
2012
|
1.63
|
67
|
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
|
J Clin Oncol
|
2012
|
1.62
|
68
|
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
|
J Clin Oncol
|
2011
|
1.56
|
69
|
FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.
|
Cancer Invest
|
2008
|
1.56
|
70
|
NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial.
|
Ann Surg Oncol
|
2004
|
1.56
|
71
|
Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials.
|
J Clin Oncol
|
2003
|
1.56
|
72
|
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
|
Breast Cancer Res Treat
|
2008
|
1.56
|
73
|
Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.
|
J Clin Oncol
|
2010
|
1.54
|
74
|
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
|
Am J Obstet Gynecol
|
2011
|
1.48
|
75
|
Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer.
|
Ann Surg Oncol
|
2008
|
1.48
|
76
|
Is sentinel node biopsy necessary in conservatively treated DCIS?
|
Ann Surg Oncol
|
2007
|
1.48
|
77
|
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.
|
J Clin Oncol
|
2010
|
1.47
|
78
|
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
|
J Clin Oncol
|
2012
|
1.46
|
79
|
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
|
J Clin Oncol
|
2013
|
1.46
|
80
|
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
|
Breast Cancer Res Treat
|
2008
|
1.41
|
81
|
Amenorrhea from breast cancer therapy--not a matter of dose.
|
N Engl J Med
|
2010
|
1.40
|
82
|
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2011
|
1.32
|
83
|
Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma.
|
Cancer
|
2005
|
1.31
|
84
|
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
|
Ann Surg Oncol
|
2010
|
1.27
|
85
|
Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women.
|
Breast Cancer Res Treat
|
2007
|
1.27
|
86
|
Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
|
J Natl Cancer Inst
|
2006
|
1.27
|
87
|
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
|
Cancer
|
2007
|
1.25
|
88
|
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
|
J Clin Oncol
|
2009
|
1.25
|
89
|
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.
|
J Clin Oncol
|
2009
|
1.24
|
90
|
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
|
Cancer
|
2004
|
1.22
|
91
|
Lower-category benign breast disease and the risk of invasive breast cancer.
|
J Natl Cancer Inst
|
2004
|
1.19
|
92
|
Role of anthracyclines in the treatment of early breast cancer.
|
J Clin Oncol
|
2009
|
1.16
|
93
|
Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
|
Breast Cancer Res Treat
|
2004
|
1.15
|
94
|
Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
|
Clin Cancer Res
|
2008
|
1.13
|
95
|
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
|
J Natl Cancer Inst
|
2011
|
1.12
|
96
|
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
|
Cancer Discov
|
2013
|
1.12
|
97
|
Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.
|
J Clin Oncol
|
2007
|
1.07
|
98
|
Pathologic variables predictive of breast events in patients with ductal carcinoma in situ.
|
Am J Clin Pathol
|
2007
|
1.06
|
99
|
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
|
Clin Breast Cancer
|
2008
|
1.04
|
100
|
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
|
J Natl Cancer Inst
|
2006
|
1.03
|
101
|
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
|
Clin Breast Cancer
|
2010
|
1.00
|
102
|
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
|
Cancer Chemother Pharmacol
|
2013
|
1.00
|
103
|
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
|
Clin Cancer Res
|
2011
|
0.98
|
104
|
Effects of tamoxifen on benign breast disease in women at high risk for breast cancer.
|
J Natl Cancer Inst
|
2003
|
0.98
|
105
|
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
|
J Clin Oncol
|
2010
|
0.96
|
106
|
Lack of influence of cytokeratin-positive mini micrometastases in "Negative Node" patients with colorectal cancer: findings from the national surgical adjuvant breast and bowel projects protocols R-01 and C-01.
|
Dis Colon Rectum
|
2003
|
0.94
|
107
|
Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04.
|
Ann Surg
|
2015
|
0.94
|
108
|
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.
|
Cancer
|
2012
|
0.93
|
109
|
Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial.
|
J Natl Cancer Inst
|
2009
|
0.93
|
110
|
National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
|
Clin Trials
|
2013
|
0.91
|
111
|
Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches.
|
J Clin Oncol
|
2007
|
0.91
|
112
|
The use of tamoxifen and raloxifene for the prevention of breast cancer.
|
Recent Results Cancer Res
|
2009
|
0.89
|
113
|
Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
|
J Clin Oncol
|
2006
|
0.89
|
114
|
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
|
J Natl Cancer Inst
|
2013
|
0.89
|
115
|
Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.
|
Clin Colorectal Cancer
|
2005
|
0.87
|
116
|
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
|
Clin Breast Cancer
|
2002
|
0.86
|
117
|
Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21.
|
Cancer
|
2007
|
0.86
|
118
|
Predictive value of microsatellite instability-high remains controversial.
|
J Clin Oncol
|
2007
|
0.84
|
119
|
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
|
Invest New Drugs
|
2007
|
0.83
|
120
|
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
|
Clin Breast Cancer
|
2011
|
0.83
|
121
|
An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma.
|
Am J Clin Oncol
|
2007
|
0.83
|
122
|
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
|
Clin Breast Cancer
|
2006
|
0.83
|
123
|
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.
|
Breast Cancer Res Treat
|
2013
|
0.83
|
124
|
Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04.
|
J Clin Oncol
|
2005
|
0.80
|
125
|
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
|
Breast Cancer Res Treat
|
2015
|
0.79
|
126
|
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).
|
Cancer Prev Res (Phila)
|
2012
|
0.79
|
127
|
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
|
J Natl Cancer Inst Monogr
|
2010
|
0.79
|
128
|
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
|
Breast Cancer Res Treat
|
2015
|
0.78
|
129
|
Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation" Int J Radiat Oncol Biol Phys 2009;75:1290-1296).
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.77
|
130
|
Is tamoxifen a risk factor for retinal vaso-occlusive disease?
|
Retina
|
2005
|
0.76
|
131
|
Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer.
|
Am J Surg
|
2002
|
0.76
|
132
|
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.
|
Semin Oncol
|
2008
|
0.75
|
133
|
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
|
Breast Cancer Res Treat
|
2015
|
0.75
|
134
|
Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32.
|
J Support Oncol
|
2013
|
0.75
|
135
|
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
|
Clin Breast Cancer
|
2008
|
0.75
|